Testing revealed weight loss effects some Wall Street analysts believe compare favorably to Lilly’s orforglipron, which ...

Analysts remain intrigued by aleniglipron’s potential in the oral GLP-1RA market, though they note it is too early to compare the drug’s efficacy to Eli Lilly’s orforglipron.

Structure Therapeutics has touted the 16% weight loss—about 39 pounds—seen by aleniglipron as the best results yet for an ...

Structure Therapeutics’ aleniglipron Phase 2 shows ~16% placebo-adjusted weight loss; a best-in-class oral GLP-1 with strong ...

Placebo-adjusted mean weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks with no evidence of weight loss plateau in ...

Five years after Virginia legalized possession of small amounts of marijuana but failed to create a way for people to legally ...

Inside a diseased cell, the genes are in chaos. Some are receiving signals to overproduce a protein. Others are reducing ...

Kidney Disease,” an editorially independent special report that was produced with financial support from Vertex. M ore than ...

AI protein function prediction uses machine learning models trained on sequence and structural data to infer protein roles at ...

By Puyaan Singh and Sahil Pandey March 16 (Reuters) - Structure Therapeutics said on Monday its pill helped patients lose up ...

Structure Therapeutics’ oral obesity drug elicited a placebo-adjusted weight loss of 16.3% at 44 weeks in a Phase 2 trial.

Chemists from St. Petersburg University has developed a new family of luminescent iridium complexes that, for the first time, realize a unique mechanism of photoactivated proton transfer. In the ...